PD-L1 Cancer Research Results

PD-L1, Programmed Death-Ligand 1: Click to Expand ⟱
Source:
Type:
PD-L1 is a protein that plays a crucial role in the regulation of the immune system. PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection.
PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers.
Scientific Papers found: Click to Expand⟱
8758- MeSA,    Targeting transforming growth factor-β1 by methylseleninic acid/seleno-L-methionine in clear cell renal cell carcinoma: Mechanisms and therapeutic potential
- vitro+vivo, RCC, 786-O - in-vitro, Kidney, Caki-1
TGF-β1↓, PD-L1↓, VEGF↓, TumCG↓,
8760- MeSA,  Cisplatin,    Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer
- vitro+vivo, Lung, NA - in-vitro, Pca, NA
PD-L1↓, ChemoSen↑, T-Cell↑,
8762- MeSA,    Methylseleninic Acid Sensitizes Ovarian Cancer Cells to T-Cell Mediated Killing by Decreasing PDL1 and VEGF Levels
- in-vitro, Ovarian, A2780S
selectivity↑, NK cell↑, T-Cell↑, PD-L1↓, Hif1a↓, VEGF↓, ROS↑, *NRF2↑,
8707- MET,    Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study
- Review, Var, NA - Review, AD, NA
*BioAv↝, *cardioP↑, *Obesity↓, *neuroP↑, *toxicity↝, *Dose↝, *GutMicro↑, *AMPK↑, *glucose↓, *NLRP3↑, *Inflam↓, *Stroke↓, *Cartilage↑, FOXP3↑, TumAuto↑, mTOR↓, PD-L1↓, RadioS↑, ChemoSen↑, ROS↓, OXPHOS↓, compI↓, Glycolysis↝, TumCP↓, *BioAv↝, *AntiAge↑, *SIRT1↑, *cognitive↑, *Risk↓, Ki-67↓, Synergy↝, PFS∅, OS∅,
1043- MET,  immuno,    Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
- in-vitro, Var, NA
Synergy↑, PD-L1↓, Ki-67↑, TIM-3↑, L-sel↑,
516- MFrot,  immuno,  MF,    Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- vitro+vivo, GBM, U87MG
TumCP↓, Apoptosis↑, TumCMig↓, ROS↑, PD-L1↑, TumVol↓, eff↑, *toxicity∅, eff↑, *toxicity∅, Dose↝, tumCV↓, TumCI↓,
1042- MLT,    Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H460 - in-vitro, Lung, LLC1
PD-L1↓, YAP/TEAD↓, TAZ↓, TumCG↓,
1044- Myr,    Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells
- in-vitro, Lung, NA
PD-L1↓, IDO1↓,
5603- NaHCO3,  immuno,    Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors
- in-vitro, BC, MCF7 - in-vitro, PC, MIA PaCa-2 - in-vitro, GBM, U87MG
eff↑, e-pH↑, PD-L1↓,
5602- NaHCO3,  immuno,    Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model
- in-vivo, BC, 4T1
Synergy↑, TumCG↓, OS↑, e-pH↑, IFN-γ↑, IL2↑, IL12↑, Dose↝, PD-L1↓,
5254- NCL,    The magic bullet: Niclosamide
- Review, Var, NA
Wnt↓, β-catenin/ZEB1↓, RAS↓, STAT3↓, NOTCH↓, E2Fs↓, mTOR↓, Synergy↑, PD-1↓, PD-L1↓, BioAv↝, toxicity↓, BioAv↑, ETC↑, NADH:NAD↓, TCA↑, Warburg↓, Diff↑, AMPK↑, P53↑, PP2A↑, HIF-1↓, KRAS↓, Myc↓, RadioS↑, ChemoSen↑, Dose↝, Dose↑,
1045- OLST,    Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line
- in-vitro, AML, Jurkat
FASN↓, TumCG↓, PD-L1↓,
1813- Oxy,    Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment
- Review, Var, NA
ChemoSen↑, RadioS↑, PD-L1↓, Hif1a↓, ROS↑,
1047- RES,    Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells
- in-vitro, Lung, H1299 - in-vitro, Lung, A549 - in-vitro, Lung, H460
PD-L1↑, Snail↑, E-cadherin↓, N-cadherin↑, Fibronectin↑, Vim↑, Axin2↓,
1048- RosA,  GSL,    Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis
- in-vivo, Colon, MC38
TumCMig↓, TumCI↓, PD-1↓, COX2/PTGS2↓, PD-L1↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, Var, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27/CDKN1B↑, COX2/PTGS2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1/SREBF1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3323- SIL,    Anticancer therapeutic potential of silibinin: current trends, scope and relevance
- Review, Var, NA
Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2/PTGS2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1/CCND1↓, E2Fs↓,
1001- SIL,    Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
- in-vitro, NPC, NA
TumCG↓, Glycolysis↓, OXPHOS↑, LDHA↓, lactateProd↓, i-citrate↑, Hif1a↓, PD-L1↓,
1049- SK,    Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2
- in-vivo, Var, NA
TNF-α↓, IL6↓, IFN-γ↓, IL1β↓, PD-L1↓, p‑PKM2↓,
1052- TQ,    Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD-L1 in MDA-MB-231 Triple-Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
NRF2↑, PD-L1↓, Apoptosis↑,
1929- TQ,    Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells
- in-vitro, Bladder, 5637 - in-vitro, Bladder, T24/HTB-9
tumCV↓, TumCP↓, TumCI↓, Casp↑, ROS↑, PD-L1↓, EMT↓, MMP↓, eff↓,
4538- TQ,    PD-L1_in_MDA-MB-231_Triple-Negative_Breast_Cancer_Cells">Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD‐L1 in MDA‐MB‐231 Triple‐Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
antiOx↑, H2O2↓, Catalase↑, SOD↑, GSH↑, PRNP↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, chemoPv↑, ROS↓,
3399- TQ,    Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - NA, BC, MDA-MB-468
ROS↓, H2O2↓, Catalase↑, SOD↑, GSH↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, GSSG↑, GPx1⇅, GPx4↓,
8159- UsA,    Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD-L1 expression and enhancing T-lymphocyte tumor-killing activity
- in-vitro, Cerv, HeLa
STAT3↓, RAS↓, mTOR↓, PD-L1↓, TumCP↓, angioG↓, TumCMig↓, TumCI↓, TumCG↓,
3141- VitC,    High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer
- in-vitro, CRC, HCT116
Glycolysis↓, Synergy↑, PD-L1↓, AMPK↑, HK2↓, NF-kB↓, Warburg↓, tumCV↓, GLUT1↓, PKM2↓, LDHA↓, CD4+↑, CD8+↑,

Showing Research Papers: 51 to 75 of 75
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 75

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 2,   Catalase↓, 1,   Catalase↑, 2,   Copper↑, 1,   GCLM↑, 2,   GPx1⇅, 1,   GPx4↓, 5,   GSH↓, 4,   GSH↑, 2,   GSSG↑, 1,   H2O2↓, 2,   HO-1↓, 2,   HO-2↓, 1,   Iron↑, 1,   c-Iron↑, 1,   lipid-P↑, 3,   MDA↑, 1,   NQO1↑, 2,   NRF2↓, 2,   NRF2↑, 3,   PrxII↓, 1,   ROS↓, 6,   ROS↑, 19,   SOD↓, 1,   SOD↑, 2,   TAC↓, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 1,   CDC25↓, 1,   compI↓, 1,   EGF↓, 1,   ETC↑, 1,   mtDam↑, 2,   OXPHOS↓, 2,   OXPHOS↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY↓, 1,   ACSL4↑, 1,   AMPK↑, 5,   ATP↓, 4,   mt-ATP↓, 1,   i-citrate↑, 1,   ECAR↝, 1,   FASN↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 6,   Glycolysis↝, 1,   GSK‐3β↓, 2,   HK2↓, 3,   IDO1↓, 1,   lactateProd↓, 2,   LDHA↓, 2,   LDL↓, 1,   NADH:NAD↓, 1,   PDK1 / PDPK1?, 2,   PDK1 / PDPK1↓, 2,   PDK3↑, 1,   PKM2↓, 2,   p‑PKM2↓, 1,   SIRT1↓, 3,   SIRT1↑, 1,   SREBP1/SREBF1↓, 1,   TCA↑, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

AIF↑, 1,   APAF1↑, 1,   Apoptosis↑, 15,   mt-Apoptosis↑, 1,   BAD↑, 3,   Bak↑, 2,   BAX↑, 8,   Bax:Bcl2↑, 3,   Bcl-2↓, 8,   Bcl-xL↓, 5,   Casp↑, 6,   Casp3↑, 6,   cl‑Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 3,   cFLIP↓, 1,   Cyt‑c↑, 7,   Diablo↑, 1,   DR5↑, 3,   Fas↑, 2,   FasL↑, 1,   Ferroptosis↑, 4,   GranA↓, 1,   GranB/GZMB↓, 1,   GranB/GZMB↑, 1,   GranB/GZMB↝, 1,   IAP1↓, 1,   ICD↑, 1,   iNOS↓, 1,   Mcl-1↓, 1,   MDM2↓, 2,   NOXA↑, 1,   p38↑, 1,   Perforin↓, 1,   Perforin↑, 1,   Perforin↝, 1,   PUMA↑, 1,   sFasL↑, 1,   survivin↓, 5,   TumCD↑, 1,   XIAP↓, 5,   YAP/TEAD↓, 1,   p‑YAP/TEAD↝, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 8,   Akt↑, 1,   p‑Akt↓, 4,   p‑cMET↑, 1,   EGFR↓, 4,   p‑EGFR↓, 2,   ERK↓, 4,   ERK↑, 1,   p‑ERK↓, 1,   HER2/EBBR2↓, 2,   p‑IKKα↓, 1,   JAK↓, 1,   JAK2↓, 4,   JNK↓, 1,   JNK↑, 1,   LIMK1↓, 1,   MAPK↓, 1,   p‑MEK↓, 1,   MOB1↓, 1,   mTOR↓, 9,   mTOR↑, 1,   p‑mTOR↓, 2,   P70S6K↓, 3,   PI3K↓, 7,   p‑PI3K↓, 1,   PKCδ↓, 3,   PP2A↑, 2,   PRAS40↑, 1,   PTEN↑, 2,   p‑Raf↓, 1,   RAS?, 1,   RAS↓, 2,   RIP1↓, 1,   Sp1/3/4↓, 2,   STAT3↓, 11,   p‑STAT3↓, 5,   THEM4/CTMP↑, 1,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↑, 1,   cMyc↓, 3,   FOXO↑, 1,   H3K27ac∅, 1,   HATs↑, 1,   HDAC↓, 1,   HDAC1↓, 1,   HDAC10↓, 1,   HDAC8↓, 1,   miR-133a-3p↝, 1,   miR-203↑, 1,   miR-34a↓, 1,   miR-34a↑, 1,   Myc↓, 2,   Myc↑, 1,   other↑, 1,   tumCV↓, 6,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 4,   eIF2α↓, 1,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 4,   HSP90↓, 1,   IRE1↑, 1,   PERK↑, 3,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG13↑, 1,   ATG16L1↑, 1,   ATG3↑, 1,   ATG5↑, 1,   ATG7↑, 1,   Beclin-1/ATG6↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3A↑, 1,   p62↓, 1,   p62↑, 1,   RUBCN↓, 1,   TumAuto↑, 4,   ULK1/ATG1↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   DNAdam↑, 2,   P53↑, 6,   cl‑PARP↑, 5,   PCNA↓, 1,   SIRT6↑, 1,   Telomerase↓, 2,   TOP1↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↓, 3,   CDK4↓, 4,   CDK6↓, 2,   CDK8↓, 1,   Cyc↓, 1,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 5,   cycD1/CCND1↑, 1,   cycE/CCNE↓, 1,   E2Fs↓, 2,   Ki-67↓, 4,   Ki-67↑, 1,   P21↑, 5,   p27/CDKN1B↑, 3,   p‑RB1↓, 1,   TumCCA↑, 15,   WEE1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   p‑4E-BP1↓, 1,   Axin2↓, 1,   BMI1↓, 1,   CD133↓, 1,   CSCs↓, 2,   Diff↑, 1,   IGFBP3↑, 1,   Ki-67↓, 4,   Ki-67↑, 1,   NOTCH↓, 3,   NOTCH1↓, 1,   NOTCH1↑, 1,   Shh↓, 1,   STAT1↓, 1,   TAZ↓, 1,   TumCG↓, 19,   TumCP↓, 13,   Wnt↓, 5,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   CA↓, 1,   Ca+2↑, 4,   Ca+2↝, 1,   CAFs/TAFs↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 5,   EMT↓, 10,   FAK↓, 1,   p‑FAK↓, 2,   Fibronectin↑, 1,   Galectin-9↓, 1,   KRAS↓, 1,   L-sel↑, 1,   LRP1↓, 1,   MET↓, 1,   MMP-10↓, 1,   MMP2↓, 9,   MMP3↓, 1,   MMP9↓, 7,   MMP9↑, 1,   MMPs↓, 1,   MTA1↓, 1,   MUC1-C↓, 1,   N-cadherin↓, 2,   N-cadherin↑, 1,   PDGF↓, 1,   Rho↓, 1,   ROCK1↓, 3,   Slug↓, 2,   SMAD3↓, 1,   Snail↓, 3,   Snail↑, 1,   TGF-β↓, 2,   TGF-β1↓, 1,   TIMP2↓, 1,   TSC1↑, 1,   TumCI↓, 10,   TumCMig↓, 11,   TumMeta↓, 3,   Twist↓, 3,   uPA↓, 2,   Vim↓, 5,   Vim↑, 1,   Zeb1↓, 3,   α-SMA↓, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 7,   Endoglin↑, 1,   HIF-1↓, 2,   Hif1a↓, 7,   LOX1↓, 1,   TXA2↓, 1,   VEGF↓, 11,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GLUT1↓, 3,   MMP↓, 8,   NHE1↓, 2,   TRPV1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD25+↓, 1,   CD25+↑, 1,   CD4+↓, 1,   CD4+↑, 4,   CD44↓, 1,   CD8+↑, 4,   cGAS–STING↑, 1,   COX1↓, 2,   COX2/PTGS2↓, 7,   CXCR4↓, 1,   FOXP3↑, 2,   FoxP3+↓, 1,   GNLY↓, 1,   IFN-γ↓, 3,   IFN-γ↑, 2,   IL1↓, 1,   IL10↓, 1,   IL12↑, 2,   IL1β↓, 4,   IL2↓, 1,   IL2↑, 3,   IL6↓, 6,   IL8↓, 1,   Imm↑, 6,   Imm↝, 1,   Inflam↓, 2,   NF-kB↓, 11,   NK cell↑, 1,   p65↓, 1,   PD-1↓, 4,   PD-1↑, 1,   PD-L1↓, 67,   PD-L1↑, 8,   PD-L2↓, 1,   PGE2↓, 2,   PSA↓, 1,   SOCS-3↑, 1,   T-Cell↑, 9,   TILs↑, 1,   TIM-3↓, 1,   TIM-3↑, 1,   TLR4↓, 1,   TNF-α↓, 5,   TNF-α↑, 1,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

e-pH↑, 2,  

Protein Aggregation(tgid=19) ⓘ

PRNP↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 2,   BioAv↓, 7,   BioAv↑, 4,   BioAv↝, 2,   BioEnh↑, 1,   ChemoSen↑, 9,   Dose↑, 2,   Dose↝, 6,   Dose∅, 1,   eff↓, 4,   eff↑, 13,   eff↝, 1,   Half-Life↓, 2,   Half-Life↑, 1,   Half-Life↝, 1,   MDR1↓, 1,   P-gp/ABCB1↓, 3,   RadioS↑, 8,   selectivity↑, 3,   Synergy↑, 8,   Synergy↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   EGFR↓, 4,   p‑EGFR↓, 2,   HER2/EBBR2↓, 2,   IL6↓, 6,   KRAS↓, 1,   Myc↓, 2,   Myc↑, 1,   PD-L1↓, 67,   PD-L1↑, 8,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 4,   AntiTum↑, 3,   cardioP↑, 2,   chemoP↑, 5,   chemoPv↑, 1,   hepatoP↑, 2,   OS↑, 3,   OS∅, 1,   Pain↓, 1,   PFS∅, 1,   QoL↑, 1,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 3,   TumW↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 1,   Sepsis↓, 1,  
Total Targets: 391

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↑, 3,   GPx↑, 2,   GSH↑, 2,   GSTs↑, 1,   HO-1↓, 1,   lipid-P↓, 3,   MDA↓, 3,   NRF2↑, 4,   ROS↓, 7,   SOD↑, 4,   TAC↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↑, 1,   glucose↓, 1,   glucose↝, 1,   PLA2↓, 1,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↓, 1,   Casp3↓, 2,   iNOS↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↑, 2,   JNK↓, 1,   mTOR↑, 1,   PI3K↑, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 2,   other↝, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↓, 1,   GRP78/BiP↓, 1,   IRE1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

neuroG↑, 1,  

Migration(tgid=13) ⓘ

Cartilage↑, 1,   MMP9↓, 1,   PAI-1/SERPINE1↓, 1,   TIMP1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

E-sel↓, 1,   NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB∅, 2,   MMP↑, 1,   MUC5AC↓, 1,   TJ↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CCL11↓, 1,   COX2/PTGS2↓, 1,   IL10↓, 1,   IL1β↓, 1,   IL4↓, 1,   IL5↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 8,   NeuroI↓, 1,   NF-kB↓, 2,   NLRP3↓, 1,   NLRP3↑, 1,   PGE2↓, 1,   TLR2↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

PSD95↑, 1,   SNAP25↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↝, 2,   Dose↝, 1,   eff↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   BUN↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   antiAll↑, 2,   AntiArt↑, 2,   AntiCan↑, 1,   antiD↓, 1,   AntiDiabetic↑, 1,   cardioP↑, 3,   chemoP↑, 1,   cognitive↓, 1,   cognitive↑, 2,   hepatoP↑, 3,   Learn↑, 1,   memory↑, 1,   Mucositis↓, 1,   neuroP?, 1,   neuroP↑, 5,   Obesity↓, 1,   RenoP↑, 2,   Risk↓, 1,   Stroke↓, 3,   toxicity↓, 3,   toxicity↝, 1,   toxicity∅, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiP↑, 1,   AntiViral↑, 1,   Bacteria↓, 2,   GutMicro↑, 1,   Sepsis↓, 2,  
Total Targets: 100

Scientific Paper Hit Count for: PD-L1, Programmed Death-Ligand 1
9 immunotherapy
5 Baicalein
4 Luteolin
4 Thymoquinone
3 Astragalus
3 Chrysin
3 Licochalcone A
3 methylseleninic acid
3 Silymarin (Milk Thistle) silibinin
2 Apigenin (mainly Parsley)
2 Curcumin
2 Aspirin
2 beta-glucans
2 Baicalin
2 Capsaicin
2 Chlorogenic acid
2 Ellagic acid
2 Honokiol
2 Metformin
2 Bicarbonate(Sodium)
1 Silver-NanoParticles
1 Allicin (mainly Garlic)
1 Artemisinin
1 Ashwagandha(Withaferin A)
1 Berberine
1 Biochanin A
1 bempedoic acid
1 Boron
1 Butyrate
1 Trastuzumab
1 Propolis -bee glue
1 Cucurbitacin
1 Docosahexaenoic Acid
1 Disulfiram
1 Copper and Cu NanoParticles
1 EGCG (Epigallocatechin Gallate)
1 Evodiamine
1 Fucoidan
1 Gallic acid
1 Rapamycin
1 Hyperoside
1 Licorice
1 Cisplatin
1 Magnetic Field Rotating
1 Magnetic Fields
1 Melatonin
1 Myricetin
1 Niclosamide (Niclocide)
1 Orlistat
1 Oxygen, Hyperbaric
1 Resveratrol
1 Rosmarinic acid
1 Germacranolide sesquiterpene lactone
1 Shikonin
1 Usnic acid
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:243  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page